{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:59:52Z","timestamp":1790740792411,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejim.2025.07.021","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:17:00Z","timestamp":1753355820000},"page":"106425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Lipoprotein (a): A new target for pharmacological research and an option for treatment"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.07.021_bib0001","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.07.021_bib0002","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0004","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0005","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0006","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0007","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1073\/pnas.90.24.11643","article-title":"Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly","volume":"90","author":"Brunner","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2025.07.021_bib0008","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2025.07.021_bib0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2025.07.021_bib0010","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/clinchem\/42.3.436","article-title":"Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature","volume":"42","author":"Marcovina","year":"1996","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejim.2025.07.021_bib0011","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00282175","article-title":"The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen","volume":"79","author":"Frank","year":"1988","journal-title":"Hum Genet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0013","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2025.07.021_bib0014","doi-asserted-by":"crossref","first-page":"15471","DOI":"10.1074\/jbc.270.26.15471","article-title":"A two-step model for lipoprotein(a) formation","volume":"270","author":"Trieu","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2025.07.021_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00041433-199906000-00010","article-title":"The seventh myth of lipoprotein(a): where and how is it assembled?","volume":"10","author":"Dieplinger","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0016","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.jprot.2011.07.008","article-title":"Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding","volume":"74","author":"von Zychlinski","year":"2011","journal-title":"J Proteom"},{"key":"10.1016\/j.ejim.2025.07.021_bib0017","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0018","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2025.07.021_bib0019","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.ATV.16.1.129","article-title":"Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect","volume":"16","author":"Carmena","year":"1996","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41586-024-08223-0","article-title":"Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor","volume":"638","author":"Reimund","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2025.07.021_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.ejim.2025.07.021_bib0022","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","article-title":"Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a)","volume":"120","author":"Sharma","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119189","article-title":"Why has the \"lp(a) receptor\" proven so elusive?","volume":"404","author":"Lambert","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma Lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2025.07.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100336","article-title":"Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort","volume":"64","author":"Matveyenko","year":"2023","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0027","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0028","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0029","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/CIRCULATIONAHA.124.069582","article-title":"Racial differences in the burden of atherosclerotic cardiovascular disease related to elevated lipoprotein(a) levels: the ARIC study","volume":"150","author":"Grant","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0031","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77669-z","article-title":"Lipoprotein (a) is not associated with thrombus burden derived from CT pulmonary angiography in patients with acute pulmonary embolism","volume":"14","author":"Gressenberger","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2025.07.021_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2025.01.021","article-title":"Lipoprotein(a) and prothrombotic effects: evidence from a genetic association study","volume":"135","author":"Olmastroni","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0034","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0035","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0036","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0037","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0038","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0039","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"E","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0041","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jacc.2020.06.040","article-title":"Lipoprotein(a) and Family history predict cardiovascular disease risk","volume":"76","author":"Mehta","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0042","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0043","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.07.021_bib0046","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.ejhg.5200152","article-title":"Concentrations of the atherogenic lp(a) are elevated in FH","volume":"6","author":"Lingenhel","year":"1998","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0047","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0048","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijcard.2015.08.146","article-title":"Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia","volume":"201","author":"Chan","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0049","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-511X-13-65","article-title":"Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort","volume":"13","author":"Allard","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0050","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0051","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0052","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0053","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0054","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehaa1066","article-title":"Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia","volume":"42","author":"Perez de Isla","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.07.021_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2018.11.040","article-title":"Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia","volume":"281","author":"Vuorio","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0056","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0057","first-page":"2508","article-title":"Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica","volume":"40","author":"Alves","year":"2020","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0058","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0059","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis","volume":"16","author":"O'Brien","year":"1996","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0060","doi-asserted-by":"crossref","first-page":"31151","DOI":"10.1074\/jbc.270.52.31151","article-title":"Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein","volume":"270","author":"Blencowe","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2025.07.021_bib0061","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization","volume":"63","author":"Mahmut","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0062","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0063","first-page":"800","article-title":"Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients","volume":"27","author":"Teo","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0064","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart fail"},{"key":"10.1016\/j.ejim.2025.07.021_bib0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","article-title":"The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis Risk in Communities study","volume":"262","author":"Agarwala","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0066","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","article-title":"Lp(a) [Lipoprotein(a)]-related risk of heart failure is evident in whites but not in other racial\/ethnic groups","volume":"38","author":"Steffen","year":"2018","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034774","article-title":"Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study","volume":"13","author":"Januzzi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2025.07.021_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2025.03.016","article-title":"Lipoprotein(a) levels and adverse outcomes in heart failure","author":"Yadalam","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2025.07.021_bib0069","doi-asserted-by":"crossref","DOI":"10.1097\/MOL.0000000000000998","article-title":"Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances","author":"Thanigaimani","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0070","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0071","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0072","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0073","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.2174\/1381612829666221124110920","article-title":"Lipoprotein (a) levels and abdominal aortic aneurysm. A systematic review and meta-analysis","volume":"28","author":"Lampsas","year":"2022","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejim.2025.07.021_bib0074","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45720","article-title":"Association of lipoprotein(a) levels with incidence of major adverse limb events","volume":"5","author":"Guedon","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2025.07.021_bib0075","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2025.07.021_bib0076","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100726","article-title":"Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting","volume":"19","author":"Jeevanathan","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0078","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813886","article-title":"Assessment of apolipoprotein(a) isoform size using phenotypic and genotypic methods","volume":"24","author":"Fogacci","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.07.021_bib0079","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","article-title":"Finding very high lipoprotein(a): the need for routine assessment","volume":"29","author":"Nurmohamed","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0080","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0081","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.07.021_bib0082","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0083","doi-asserted-by":"crossref","DOI":"10.31083\/RCM26162","article-title":"Statins-their effect on lipoprotein(a) levels","volume":"26","author":"Granat","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0084","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with Alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 Modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by Alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ejim.2025.07.021_bib0086","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.07.021_bib0087","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.07.021_bib0088","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0089","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of Obicetrapib in patients at high cardiovascular risk","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2025.07.021_bib0091","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0092","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2025.07.021_bib0093","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0094","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.021_bib0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0096","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0097","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0098","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - A long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.021_bib0099","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0100","article-title":"Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","author":"Nissen","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0101","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0102","article-title":"Oral Muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","author":"Nicholls","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2025.07.021_bib0103","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2022.02.013","article-title":"How should public health recommendations address lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?","volume":"349","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:14:51Z","timestamp":1762337691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":103,"alternative-id":["S0953620525003048"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.021","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein (a): A new target for pharmacological research and an option for treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106425"}}